RxDoctor Payments Data

Rhea Rowser, MD

Family Medicine · Miamisburg, OHNPI 1366409328

Payments from drug & device makers

$1,256in general payments, 2019–2025

Across 65 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$393
  • Novo Nordisk$182
  • Boehringer Ingelheim$124
  • Takeda Pharmaceuticals U.S.A., Inc.$114
  • Merck$97
  • Johnson & Johnson$86
  • plus $261 from 10 others

What the payments were for

  • Food & beverage$1,24999%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,256 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$15,825
Medicare patients
65
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide35$53,611
TrulicityDulaglutide24$28,674
OzempicSemaglutide22$24,065
MounjaroTirzepatide21$21,195
EliquisApixaban24$17,296
XareltoRivaroxaban24$15,856
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,125
Atorvastatin Calcium239$1,844
Comfort Ez Pen NeedlePen Needle, Diabetic17$1,586
Ondansetron Hcl13$1,363
Amitriptyline Hcl50$1,109
Albuterol Sulfate HfaAlbuterol Sulfate62$1,024
SynthroidLevothyroxine Sodium12$1,011
Levothyroxine Sodium88$977
Omeprazole100$954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$182$77,67657 claims
Lilly USA, LLCTrulicity, Mounjaro$29$49,86945 claims
PfizerEliquis$35$17,29624 claims
Johnson & JohnsonXarelto$86$15,85624 claims
AbbVieSynthroid$81$1,01112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Miamisburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →